13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001766721
Total reported value
$471.6M
$471.6M
13 檔
97.1%
According to the latest 13F quarterly dataset, Aisling Capital Management LP managed an equity portfolio of $471.6M at the end of Q4 2025, spanning 13 distinct U.S. exchange-listed positions.
In Q4 2025, Aisling Capital Management LP adopted a defensive or profit-taking posture, trimming 1 positions and completely liquidating 2 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 81.29% | -6.87% | -16.42% | |
| 2 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 5.78% | -0.36% | — | |
| 3 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 4.82% | +2.61% | — | |
| 4 | BCAX | Bicara Therapeutics Inc | Stock-Other | 2.00% | +1.20% | — | |
| 5 | CMPS | Compass Pathways PLC | Stock-Other | 1.73% | +2.64% | — | |
| 6 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.48% | -0.27% | — | |
| 7 | CALC | Calcimedica Inc | Stock-Other | 0.72% | — | — | |
| 8 | SRRK | Scholar Rock Holding CORP | Stock-Other | 0.71% | +0.10% | — | |
| 9 | BMEA | Biomea Fusion Inc | Stock-Other | 0.53% | -0.02% | — | |
| 10 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.53% | +0.43% | — | |
| 11 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.27% | +0.15% | — | |
| 12 | MRKR | Marker Therapeutics Inc | Stock-Other | 0.10% | +0.01% | — | |
| 13 | OKUR | Onkure Therapeutics Inc-a | Stock-Other | 0.05% | +0.01% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | BBIO | Bridgebio Pharma Inc | +12% | -16.42% | Trim |
| 2 | GLUE | Monte Rosa Therapeutics Inc | +2.4% | — | Unchanged |
| 3 | SNDX | Syndax Pharmaceuticals Inc | +1.3% | — | Unchanged |
| 4 | CALC | Calcimedica Inc | +0.4% | — | Unchanged |
| 5 | CMPS | Compass Pathways PLC | +0.2% | — | Unchanged |
| 6 | ACRS | Aclaris Therapeutics Inc | +0.1% | — | Unchanged |
| 7 | SRRK | Scholar Rock Holding CORP | +0.1% | — | Unchanged |
| 8 | BBOT | Bridgebio Oncology Therapeut | +0.1% | — | Unchanged |
| 9 | MRKR | Marker Therapeutics Inc | 0% | — | Unchanged |
| 10 | BCAX | Bicara Therapeutics Inc | 0% | — | Unchanged |
| 11 | OKUR | Onkure Therapeutics Inc-a | — | — | Unchanged |
| 12 | BMEA | Biomea Fusion Inc | -0.4% | — | Unchanged |
| 13 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 14 | NUVB | Nuvation Bio Inc | — | EXIT | Sold out |
| 15 | URGN | UroGen Pharma Ltd. | — | NEW | New buy |
According to official SEC Form 13F filings, Aisling Capital Management LP reported a total U.S. public equity portfolio value of $471.6M across 13 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including BBIO, SNDX, GLUE) accounted for 97.1% of total reported equity market value during Q4 2025.
Top New Position Initiated
URGN
市值: $2.5M
Top Position Liquidated / Trimmed
VRNA
前期市值: $65.7M
During Q4 2025, Aisling Capital Management LP's top holdings by market value included BBIO (81.3%)、SNDX (5.8%)、GLUE (4.8%). The largest single position, BBIO, represented 81.3% of total portfolio value.
In Q4 2025, Aisling Capital Management LP made 4 total portfolio adjustments, initiating 1 new buys, adding to 0 positions, trimming 1 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.